Guido Oelkers, Sobi CEO
March 21, 2023 06:39 AM EDTUpdated 12:23 PM
R&D

So­bi's PhI­II gout win sets up a po­ten­tial ri­val­ry with fu­ture Am­gen as­set

Amber Tong

Al­most three years af­ter Swedish Or­phan Biovit­rum — per­haps bet­ter known as So­bi — shelled out $100 mil­lion in cash to li­cense Se­lec­ta’s ex­per­i­men­tal drug for chron­ic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times